免疫原性
双特异性抗体
生物分析
单克隆抗体
医学
计算生物学
临床试验
计算机科学
抗体
抗体疗法
透明度(行为)
抗体反应
免疫学
出处
期刊:Bioanalysis
[Future Science Ltd]
日期:2026-04-13
卷期号:18 (5-6): 517-528
被引量:1
标识
DOI:10.1080/17576180.2026.2672456
摘要
Bispecific antibodies (bsAbs) represent a rapidly expanding class of biotherapeutics that enable novel mechanisms of action beyond the conventional monoclonal antibodies (mAbs). While their clinical success continues to grow, the increased structural complexity, non-native architecture, and dual-targeting mechanisms introduce unique immunogenicity risks and sophisticated bioanalytical challenges. In this review, we examine the clinical immunogenicity profiles of approved and selected investigational bsAbs, highlighting key determinants that drive immunogenicity risk. We also discuss critical hurdles, considerations and emerging solutions in immunogenicity evaluation for bsAbs, including limitations of widely used anti-drug antibody (ADA) assay format, matrix interference, domain-specific characterization, and functional neutralization assessment. Finally, we propose an integrated immunogenicity assessment framework that combines predictive tools, clinical bioanalytical data, and reverse-translational investigations to refine therapeutic platforms and reduce immunogenicity risk in next-generation bsAb development. To support this evolution, we advocate enhanced industry transparency and the publication of immunogenicity results in detail, especially for programs terminated due to high immunogenicity. Together, these approaches aim to support more informed decision-making and enable the safe and effective advancement of complex bispecific antibody therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI